ArticleJournal of women's health (2002)2021
Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers.
Article in Journal of women's health (2002), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Factors Influencing HPV Vaccination Uptake in Adolescents: Evidence to Guide Clinical Practice.Worldviews on evidence-based nursing · 2026Review
- Urban-rural disparities in HPV vaccination knowledge, willingness, and uptake among women in the Tibet autonomous region: a multi-center cross-sectional study.Frontiers in public health · 2026Article
- HPV in Pregnancy: Implications for Screening, Vaccination, and Maternal-Fetal Health.Journal of pregnancy · 2026Review
- Assessing HPV awareness and Knowledge in Future Health Professionals: A Survey of Health Science Students in Iran.Journal of community health · 2025Article
- Educational Needs for Preventing and Managing Human Papillomavirus-Related Diseases in Men Living with HIV in Mexico.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers.Oncology and therapy · 2024Review
- Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.The Lancet. Infectious diseases · 2024Article
- Cervical cancer prevention in Burkina Faso: a stakeholder's collaboration for the development of awareness messaging.Frontiers in oncology · 2024Article
- Global disease burden attributed to unsafe sex in 204 countries and territories from 1990 to 2019: results from the Global Burden of Disease Study 2019.Scientific reports · 2023Article
- HPV Vaccination during the COVID-19 Pandemic in Italy: Opportunity Loss or Incremental Cost.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) infections cause more than 35,900 cancers annually in the United States. Although cervical cancer is the most prevalent HPV-related malignancy in women, the virus is also responsible for a significant percentage of anal, vaginal, and vulvar cancers. A comprehensive approach to mitigating cervical cancer includes HPV vaccination (primary prevention), screening and treatment of precancerous lesions (secondary prevention), and diagnosis and treatment of invasive cancer (tertiary prevention). Although a successful strategy, there are opportunities to innovate and increase access that can also be adapted to address the unique clinical care gaps that exist with the other anogenital cancers. The Society for Women's Health Research held a series of interdisciplinary meetings and events, during which expert researchers, clinicians, patient advocates, and health care policy leaders evaluated the current landscape of HPV-related cancers and their effects on women's health. This report summarizes the discussions of this working group and areas it identified in which to address gaps in primary and secondary prevention approaches to improve access and health outcomes for women with HPV-related anogenital cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.